R&D spending rebounds big in 2013

Pharma companies have taken some heat for their R&D productivity levels as of late. But drug developers and investors apparently have seen their faith restored: According to an EY report, R&D spending across the biopharma industry shot up 14% to hit $29.1 billion in 2013, reflecting renewed optimism that research can breed results. More